Capricor Therapeutics Inc (CAPR)

[QServus]

$CAPR DD Summary

Within 2 weeks there is a 12 month DMD trial results due.

Major success and approvable endpoints on 6 month DMD trial

http://irdirect.net/prviewer/release/id/4287978

There is only one major competitor in the DMD space - Sarepta’s Exondys 51 which only targets 14% of DMD patients.

https://en.m.wikipedia.org/wiki/Eteplirsen

This one targets 100% of non ambulant DMD patients which is 10,000 in USA at $200k annual cost of treatment = $2B annual revenues

12.5 million confirmed OS
1.5 million owned by management and institutions
= total float is ~11 million shares

$20 per share = $250 Million market cap

————-

Watch this DD:

Furthermore Capricor’s exosome compassionate use emergency treatment got 100% success rate and an FDA approval and nod for a further 20 patient trial - to be funded with non dilutive capital.

http://irdirect.net/prviewer/release/id/4306152

P1 and human trials might soon begin on the covid 19 vaccine seeing success with exosomes and FDA approval.

Huge opportunity